1801 - Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib

Primary Author / Presenter(s)

Britten K. Gordon, BS

Graduate Research Fellow
The Ohio State University
Columbus, Ohio, United States

Co-Author(s)

LC

Lillian M. Cool, BS

The Ohio State University
Columbues, Ohio, United States
EM

Elizabeth M. Muhowski, PhD

The Ohio State University
Columbus, Ohio, United States
LY

Lianbo Yu, PhD

The Ohio State University
Columbus, Ohio, United States
JR

Janani Ravikrishnan, PhD

The Ohio State University
Columbus, Ohio, United States
SB

Samon Benrashid, BS

The Ohio State University
Columbus, Ohio, United States
AM

Andrew D. Mitchell, MS

The Ohio State University
Columbus, Ohio, United States
AH

Alexander He, BS

The Ohio State University
Columbus, Ohio, United States
SM

Shrilekha Misra, PhD

The Ohio State University
Columbus, Ohio, United States
TL

Tzung-Huei Lai, DVM, PhD

The Ohio State University
Columbus, Ohio, United States
ST

Shanmugapriya Thangavadivel, PhD

Research Scientist
The Ohio State University
Columbus, Ohio, United States
AM

Alexander R. Marr, PhD

The Ohio State University
Columbus, Ohio, United States
JU

Jazmin M. Urrutia, BS

The Ohio State University
Columbus, Ohio, United States
CL

Casey Leimbach, BS

The Ohio State University
Columbus, Ohio, United States
NK

Naina Karnati, BS

The Ohio State University
Columbus, Ohio, United States
SZ

Serena Li Zhao, PhD

The Ohio State University
Columbus, Ohio, United States
SS

Sonam Sonam, PhD

The Ohio State University
Columbus, Ohio, United States
SK

Smita Kumari, PhD

The Ohio State University
Columbus, Ohio, United States
EP

Elizabeth Perry, BS

The Ohio State University
Columbus, Ohio, United States
KR

Kerry A. Rogers, MD

Associate Professor
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
AK

Adam S Kittai, MD

Icahn School of Medicine at Mount Sinai
New York, New York, United States
SB

Seema A. Bhat, MD

Associate Professor
The Ohio State University
Columbus, Ohio, United States
AA

Aseel Alsouqi, MD

The Ohio State University
Columbus, Ohio, United States
NM

Natarajan Muthusamy, DVM, PhD

Professor of Medicine
The Ohio State University
Columbus, Ohio, United States
JB

John C. C. Byrd, MD

University of Cincinnati
Cincinnati, Ohio, United States
Deepa Sampath, PhD

Professor
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Rosa Lapalombella, PhD

Professor
The Ohio State University
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
BP

Blake R. Peterson, PhD

The Ohio State University
Columbus, Ohio, United States
YC

Yi Chen, PhD

Newave Pharmaceutical Inc.
Pleasanton, California, United States
FT

Fenlai Tan, MD, PhD

Newave Pharmaceutical Inc.
Pleasanton, California, United States
SA

Stephen P. Anthony, DO

Newave Pharmaceutical Inc.
Pleasanton, California, United States
YC

Yu Chen, MD, PhD

Newave Pharmaceutical Inc.
Pleasanton, California, United States
Jennifer A. Woyach, MD

Professor of Medicine
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States